Table 2 The features of neoadjuvant and adjuvant groups
From: Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Neoadjuvant group n = 34 | Adjuvant group n = 29 | P-value | |
|---|---|---|---|
Age | 62.2 (42.9–75.6) | 59.6 (40.5–77.1) | 0.052 |
Female sex | 4 (11.8%) | 2 (6.9%) | 0.416 |
ECOG-PS | 1 (0–2) | 1 (0–3) | 0.465 |
Smoking history | 22 | 23 | 0.316 |
Stage | |||
2 | 6 (17.6%) | 0 | 0.024 |
3a | 9 (26.5%) | 16 (55.2%) | |
3b | 18 (52.9%) | 13 (44.8%) | |
Estimated GFR | 84 (50–114) | 80 (46–125) | 0.488 |
Hb, g/dl | 13.1 (7.7–16.7) | 13.0 (8.1–16.5) | 0.737 |
WBC, × 109/mm3 | 8.1 (2.5–13.4) | 8.8 (4.4–16.4) | 0.076 |
Neutrophil, × 109/mm3 | 5.0 (1.4–11.6) | 6.1 (2.6–13.5) | 0.059 |
Platelet, × 109/mm3 | 270 (127–641) | 287 (181–861) | 0.551 |
LDH, U/l | 193 (127–348) | 178 (134–329) | 0.136 |
CRP, mg/dl | 30.5 (1.2–198) | 31.5 (2–142) | 0.899 |
Albumin, g/dl | 4.4 (3.2–5) | 4.5 (2.7–4.9) | 0.890 |
Non-survivor | 17 (50%) | 9 (31%) | 0.205 |